First example of hemolytic disease of the newborn caused by anti-Or and confirmation of the molecular basis of Or.
OBJECTIVE
The rare MNS antigen Or (MNS31) is sensitive to ficin, papain and sialidase, but partially resistant to trypsin (0.05%); the effect of alpha-chymotrypsin is not known. A point mutation, 204C --> T in exon 3 of GYPA, is associated with the Or+ phenotype. We report here the first case of hemolytic disease of the newborn (HDN) caused by anti-Or, and expand the information on the nature of the Or determinant.


METHODS
A woman, gravida 4, para 0, delivered a baby whose red blood cells (RBCs) were positive (2+) on the direct antiglobulin test (DAT). The mother's serum, an eluate made from the baby's RBCs and the RBCs of the baby's father were investigated. Exon 3 of GYPA, extracted from the father's genomic DNA, was amplified and sequenced.


RESULTS
The mother's serum reacted at room temperature, 37 degrees C and on the indirect antiglobulin test with RBCs from the baby's father. The father's RBCs were M+N+S-s+Or+. The antibody in the mother's serum and in the baby's eluate was identified as anti-Or. The serum did not react with the father's RBCs treated with trypsin (180,000 U/ml), but did react with his alpha-chymotrypsin-treated RBCs. Amplification and sequencing of DNA from the father revealed a single point mutation, 204C --> T, in GYPA exon 3. At birth, the baby had clinical symptoms of HDN and was transfused with 36 ml of packed RBCs and received phototherapy for eight days. At week 11, the baby's M+N+S+s+Or+ RBCs were negative on the DAT.


CONCLUSIONS
This is the first case of HDN caused by anti-Or. The observed point mutation, 204C --> T, confirms that of a previous report and predicts a change of Arg (Or-) to Trp (Or+) at amino acid 31.
Reid
M E
ME
New York Blood Center, New York, NY 10021, USA. mreid@nybc.org
Sausais
L
L
Oyen
R
R
Storry
J R
JR
Shukla
H
H
Hsu
T
T
Lim
S M
SM
D000328:Adult; D019943:Amino Acid Substitution; D002918:Chymotrypsin / Q000494:pharmacology; D003298:Coombs Test; D004252:DNA Mutational Analysis; D004229:Dithiothreitol / Q000494:pharmacology; D000939:Epitopes / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D004899:Erythroblastosis, Fetal / Q000235:genetics / Q000276:immunology*; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000276:immunology; D005260:Female; D006021:Glycophorins / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies / Q000276:immunology; D008951:MNSs Blood-Group System; D008297:Male; D008431:Maternal-Fetal Exchange; D010206:Papain / Q000494:pharmacology; D010641:Phenotype; D017354:Point Mutation; D011247:Pregnancy; D014357:Trypsin / Q000494:pharmacology
D000939:Epitopes; D006021:Glycophorins; D007518:Isoantibodies; D008951:MNSs Blood-Group System; D002918:Chymotrypsin; C117608:alpha-chymotrypsin; D014357:Trypsin; D010206:Papain; D004229:Dithiothreitol